Evidence map›Paper›PMID 32444869›Full record

ArticleMolecular psychiatry2020

Amyloidogenic processing of Alzheimer's disease β-amyloid precursor protein induces cellular iron retention.

Andrew Tsatsanis, Bruce X Wong, Adam P Gunn, Scott Ayton, Ashley I Bush, David Devos, James A Duce

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 80 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Cerebral amyloid angiopathy: a narrative review.Frontiers in aging neuroscience · 2025
    Review
  10. The Azalea Hypothesis of Alzheimer Disease: A Functional Iron Deficiency Promotes Neurodegeneration.The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry · 2024
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Andrew Tsatsanis *The ALBORADA Drug Discovery Institute, University of Cambridge, Cambridge Biomedical Campus, Hills Road, Cambridge, UK.
Bruce X Wong *The ALBORADA Drug Discovery Institute, University of Cambridge, Cambridge Biomedical Campus, Hills Road, Cambridge, UK.
Adam P GunnMelbourne Dementia Research Centre, The Florey Institute of Neuroscience and Mental Health, and The University of Melbourne, Parkville, VIC, Australia.
Scott AytonMelbourne Dementia Research Centre, The Florey Institute of Neuroscience and Mental Health, and The University of Melbourne, Parkville, VIC, Australia.
Ashley I BushMelbourne Dementia Research Centre, The Florey Institute of Neuroscience and Mental Health, and The University of Melbourne, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0001-8259-9069
David DevosDepartment of Medical Pharmacology, Lille University, INSERM UMRS_1171, University Hospital Center, Lille, France.
James A DuceThe ALBORADA Drug Discovery Institute, University of Cambridge, Cambridge Biomedical Campus, Hills Road, Cambridge, UK. jad205@cam.ac.uk.ORCID http://orcid.org/0000-0002-8762-2245
University of Leeds · GBInserm · FRThe University of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The proteolytic cleavage of β-amyloid precursor protein (APP) to form the amyloid beta (Aβ) peptide is related to the pathogenesis of Alzheimer's disease (AD) because APP mutations that influence this processing either induce familial AD or mitigate the risk of AD. Yet Aβ formation itself may not be pathogenic. APP promotes neuronal iron efflux by stabilizing the cell-surface presentation of ferroportin, the only iron export channel of cells. Mislocalization of APP can promote iron retention, thus we hypothesized that changes in endocytotic trafficking associated with altered APP processing could contribute to the neuronal iron elevation and oxidative burden that feature in AD pathology. Here, we demonstrate, using genetic and pharmacological approaches, that endocytotic amyloidogenic processing of APP impairs iron export by destabilizing ferroportin on the cell surface. Conversely, preferential non-amyloidogenic processing of APP at the cell surface promotes ferroportin stabilization to decrease intraneuronal iron. A new Aβ-independent hypothesis emerges where the amyloidogenic processing of APP, combined with age-dependent iron elevation in the tissue, increases pro-oxidant iron burden in AD.

Indexed as

Alzheimer DiseaseAmyloid beta-Protein PrecursorAmyloid beta-PeptidesAmyloid Precursor Protein SecretasesHumansIronNeuronsAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAmyloid Precursor Protein SecretasesIron

Identifiers

PMID32444869
OpenAlexW3027333525

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.